Andrew is a senior M&A and equity capital markets lawyer with extensive experience in public and private mergers and acquisitions, IPOs and secondary offerings, joint ventures and private financing rounds.
He is one of only six London lawyers to be ranked in Tier 1 for mid-market M&A by Chambers UK legal directory as well as being listed as one of The Lawyer's Hot 100. As quoted in the legal directories, Andrew's clients describe him as 'a strong negotiator and problem solver' as well as being 'Incredibly pragmatic. The perfect sounding board for our business.'
Andrew is the UK Head of Corporate Life Sciences and is recognised within the legal directories as a 'very talented' corporate and commercial lawyer with a long-standing commitment to the biotechnology and pharmaceutical industries.
While at his previous firm, Andrew led the team on the contested public takeover of his long-standing client Lavendon Group plc, a transaction which garnered industry recognition at The Legal Business Awards.
Hall of fame
Leading partner
Corporate/M&A £100-800 million - Band 1: “Andrew Edge is an excellent corporate lawyer” and “Andrew delivers the whole firm and he is highly proactive at identifying potential risks and mitigating actions ahead of time”.
Corporate/M&A (mid market) - Band 1: Andrew Edge is a foremost corporate practitioner to whom clients look for advice on their more significant transactions. He provides outstanding counsel on mid-market M&A and joint ventures. "Andrew Edge is a very talented lawyer; a really good operator generally." "He's got a very good practice, particularly in life sciences and tech."
M&A - lower mid-market deals, £50m-£500m (Next generation partner)
We have won Life Sciences Team of the Year at the Legal Business Awards 2023 for advising on three simultaneous transformational transactions for AIM-listed Shield Therapeutics plc.
Press releaseWe advised Apollo Therapeutics in their USD226.5 million series C fundraising. Apollo aims to advance pipeline programs through clinical development and further fund the company’s drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions, which include The Institute of Cancer Research.
Press releasepar plusieurs auteurs
Advising on RSM UK's strategic investment in RSM Ireland
par plusieurs auteurs
Advising Shield Therapeutics on securing $26 million debt and equity fundraising
par Andrew Edge
par plusieurs auteurs
par Toon Rummens
par Lorraine Smith et Kerry Buckenham
par plusieurs auteurs
par plusieurs auteurs
par plusieurs auteurs
par Ross McNaughton et Oli Denne
par plusieurs auteurs
par Michal Zabost